Axa
KYMR icon

Axa’s Kymera Therapeutics KYMR Stock Holding History

Axa’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90,971
Closed -$3.97M – 611
2025
Q2 		$3.97M Sell
90,971
-18,023
-17% -$621K 0.01% 609
2025
Q1 		$2.98M Sell
108,994
-142
-0.1% -$5.18K 0.01% 648
2024
Q4 		$4.39M Sell
109,136
-176
-0.2% -$7.95K 0.01% 573
2024
Q3 		$5.17M Buy
109,312
+33
+0% +$1.46K 0.02% 535
2024
Q2 		$3.26M Buy
109,279
+62
+0.1% +$2.15K 0.01% 646
2024
Q1 		$4.39M Buy
+109,217
New +$3.91M 0.01% 586

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Axa's KYMR Position: Q3 2025 in Review

Axa sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 90,971 shares — an estimated $3.97M sold.

Axa first reported a position in KYMR in Q1 2024 and held it in 6 quarters. The position peaked at $5.17M in Q3 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Axa reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 90,971 Kymera Therapeutics shares in Q3 2025, an estimated $3.97M.
  • Axa first reported a position in Kymera Therapeutics in Q1 2024 and held it in 6 quarters.
  • Axa's Kymera Therapeutics position peaked at $5.17M in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.